Trial · NCT07914218
Rural Veteran and Care Partner Walking Program
NCT07914218, Not applicable, Recruiting, Creighton University
3 sourcestrials-2026-11-12-0.4.0
Cite this record
ConductScience Library. Rural Veteran and Care Partner Walking Program. Trials, record NCT07914218. Release trials-2026-11-12-0.4.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07914218
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Rural Veteran and Care Partner Walking Program
- NCT number
- NCT07914218
- Status
- Recruiting
- Phases
- Not applicable
- Enrollment
- 12 participants, estimated
- Lead sponsor
- Creighton University
- Conditions
- Mild Cognitive Impairment (MCI)
- Interventions
- Telerehabilitation Physical Activity Behavioral Intervention
- First posted
- 2026-11-03
- Last updated
- 2026-11-03
Source ClinicalTrials.gov
Registered outcomes6
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Weekly Session Attendance | From enrollment to end of the 6-week intervention | The total number of sessions attended by dyads will be reported as a percentage of the 6 weekly sessions. Ranges of attendance could be 0% (not attending any sessions) to 100% attending all session. Attendance will be used to evaluate participant engagement and practicality of implementation. |
| Primary | Study Retention | From enrollment to end of intervention at 8 weeks | Defined as continued participation through the study completion. Calculated using withdrawal and completion records. Higher retention (such as 100% retention indicating all dyads that enrolled in the study, completed the study) supports intervention feasibility. |
| Primary | Intrinsic Motivation Inventory (IMI) | Post-intervention (week 8) | Evaluates participant interest, enjoyment, perceived value, and engagement with the intervention. The IMI is comprised of 7 statements related to interest/enjoyment that the participant indicates how true the statement is to them regarding their experience participating in the intervention. Each statement is scored on a 1-7 scale and an average is computed across all the questions to determine the IMI score. Higher scores indicate greater intervention acceptability. |
| Primary | Number of participants with study-related adverse events | From enrollment to end of intervention at 8 weeks | Includes falls, injuries, medical issues, skin irritation, or other unintended consequences. Used to evaluate intervention safety. |
| Primary | Average Daily Stepping | Pre (before starting the 6-week walking program) and Post Intervention (following completion of the 6-week walking program) | Objective measure of physical activity captured through Fitbit devices. Average daily step counts are computed in the Fitbit application and will be recorded for each day and averaged over the 7-day monitoring period before and after the intervention provide proof-of-concept evidence of behavior change. |
| Primary | Qualitative Intervention Feasibility Outcomes | Post-intervention (for feedback) | Interviews evaluating demand, implementation, practicality, acceptability, adaptation, and integration. Findings will guide refinement of the intervention for future trials. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07914218
GET https://conductscience.org/api/trials/v1/NCT07914218/registered